Healthcare provider profile · identity verified

Theresa N Tran, MD

Endocrinology · RENTON, WA · NPI 1992835607

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	565	149
Ozempic	Semaglutide	435	95
Atorvastatin Calcium	Atorvastatin Calcium	415	126
Jardiance	Empagliflozin	357	93
Metformin Hcl Er	Metformin Hcl	283	81
Metformin Hcl	Metformin Hcl	272	75
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	230	80
Glipizide	Glipizide	138	44
Methimazole	Methimazole	137	39
Humalog Kwikpen U-100	Insulin Lispro	129	44
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	121	49
Novolog Flexpen	Insulin Aspart	119	52
Lisinopril	Lisinopril	109	36
Rosuvastatin Calcium	Rosuvastatin Calcium	102	30
Trulicity	Dulaglutide	95	21
Synthroid	Levothyroxine Sodium	94	25
Mounjaro	Tirzepatide	91	20
Losartan Potassium	Losartan Potassium	88	26
Tresiba Flextouch U-200	Insulin Degludec	80	21
Tresiba Flextouch U-100	Insulin Degludec	77	26
Pioglitazone Hcl	Pioglitazone Hcl	73	20
Novolog	Insulin Aspart	71	24
Alendronate Sodium	Alendronate Sodium	70	23
Humalog	Insulin Lispro	70	23
Amlodipine Besylate	Amlodipine Besylate	69	23
Droplet Pen Needle	Pen Needle, Diabetic	68	22
Farxiga	Dapagliflozin Propanediol	68	16
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	64	25
Ezetimibe	Ezetimibe	62	19
Gabapentin	Gabapentin	59	17
Simvastatin	Simvastatin	59	21
Insulin Lispro Kwikpen U-100	Insulin Lispro	53	24
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	52	15
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	47	13
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	45	14
Lantus	Insulin Glargine,hum.Rec.Anlog	43	12
Humalog Kwikpen U-200	Insulin Lispro	37	suppressed
Rybelsus	Semaglutide	37	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	35	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	33	suppressed
Testosterone	Testosterone	33	suppressed
Liothyronine Sodium	Liothyronine Sodium	32	suppressed
Victoza 3-Pak	Liraglutide	32	12
Carvedilol	Carvedilol	29	suppressed
Hydrocortisone	Hydrocortisone	29	suppressed
Testosterone Cypionate	Testosterone Cypionate	29	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	28	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	28	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	26	suppressed
Metoprolol Succinate	Metoprolol Succinate	25	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	24	suppressed
Levemir Flexpen	Insulin Detemir	23	11
Topiramate	Topiramate	23	suppressed
Omnipod 5 Dexg7g6 Pods (Gen 5)	Insulin Pump Cart,auto,bt,g6/7	22	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	22	suppressed
Ibandronate Sodium	Ibandronate Sodium	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Trueplus Pen Needle	Pen Needle, Diabetic	19	suppressed
Ultra-Fine Micro Pen Needle	Pen Needle, Diabetic	19	suppressed
Calcitriol	Calcitriol	18	suppressed
Insulin Lispro	Insulin Lispro	18	11
Atenolol	Atenolol	17	suppressed
Invokana	Canagliflozin	17	suppressed
Prednisone	Prednisone	17	suppressed
Januvia	Sitagliptin Phosphate	16	suppressed
Novolin N Flexpen	Insulin Nph Human Isophane	16	suppressed
Bydureon Bcise	Exenatide Microspheres	15	suppressed
Repaglinide	Repaglinide	15	suppressed
Desmopressin Acetate	Desmopressin Acetate	14	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	14	suppressed
Pravastatin Sodium	Pravastatin Sodium	14	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Humulin R U-500	Insulin Regular, Human	13	suppressed
Insulin Aspart Flexpen	Insulin Aspart	13	suppressed
Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	13	suppressed
Bromocriptine Mesylate	Bromocriptine Mesylate	12	suppressed
Duloxetine Hcl	Duloxetine Hcl	12	suppressed
Estradiol Valerate	Estradiol Valerate	12	suppressed
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	12	suppressed
Telmisartan	Telmisartan	12	suppressed
Admelog Solostar	Insulin Lispro	11	suppressed
Humulin N	Insulin Nph Human Isophane	11	suppressed
Nateglinide	Nateglinide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error